Can fecal microbiota transplantations modulate autoimmune responses in type 1 diabetes?

Abstract

SummaryType 1 diabetes (T1D) is a chronic autoimmune disease targeting insulin‐producing pancreatic beta cells. T1D is a multifactorial disease incorporating genetic and environmental factors. In recent years, the advances in high‐throughput sequencing have allowed researchers to elucidate the changes in the gut microbiota taxonomy and functional capacity that accompany T1D development. An increasing number of studies have shown a role of the gut microbiota in mediating immune responses in health and disease, including autoimmunity. Fecal microbiota transplantations (FMT) have been largely used in murine models to prove a causal role of the gut microbiome in disease progression and have been shown to be a safe and effective treatment in inflammatory human diseases. In this review, we summarize and discuss recent research regarding the gut microbiota–host interactions in T1D, the current advancement in therapies for T1D, and the usefulness of FMT studies to explore microbiota–host immunity encounters in murine models and to shape the course of human type 1 diabetes.